scispace - formally typeset
R

Roy Kishony

Researcher at Technion – Israel Institute of Technology

Publications -  103
Citations -  13656

Roy Kishony is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Antibiotic resistance & Drug resistance. The author has an hindex of 48, co-authored 98 publications receiving 11006 citations. Previous affiliations of Roy Kishony include Tel Aviv University & Rockefeller University.

Papers
More filters
Journal ArticleDOI

Evolutionary paths to antibiotic resistance under dynamically sustained drug selection

TL;DR: A selection device, the 'morbidostat', that continuously monitors bacterial growth and dynamically regulates drug concentrations, such that the evolving population is constantly challenged, shows that parallel populations evolved similar mutations and acquired them in a similar order.
Journal ArticleDOI

Modular epistasis in yeast metabolism.

TL;DR: It is found that the ensuing epistatic interaction network could be organized hierarchically into function-enriched modules that interact with each other 'monochromatically' (i.e., with purely aggravating or purely buffering epistatic links) and provides a new definition of biological modularity, which emphasizes interactions between, rather than within, functional modules.
Journal ArticleDOI

Inexpensive Multiplexed Library Preparation for Megabase-Sized Genomes

TL;DR: A protocol for rapid and inexpensive preparation of hundreds of multiplexed genomic libraries for Illumina sequencing by carrying out the Nextera tagmentation reaction in small volumes, replacing costly reagents with cheaper equivalents, and omitting unnecessary steps is presented.
Journal ArticleDOI

Bacterial persistence: a model of survival in changing environments.

TL;DR: It is demonstrated that wild-type persistence is suited for environments in which antibiotic stress is a rare event, and that clonal bacterial populations may use persister cells, whose slow division rate under growth conditions leads to lower population fitness, as an “insurance policy” against antibiotic encounters.